Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody
PD-1 (Programmed cell death protein 1; CD279) is an immune checkpoint. PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily. Besides, It shows a role in regulating the immune system’s response by down-regulating the immune system. Meanwhile, this compound promotes self-tolerance by suppressing T-cell inflammatory activity....
ZLDI-8, an ADAM-17 and Notch Inhibitor, Enhances Chemotherapeutic Effects
ADAM metallopeptidase domain 17 (ADAM17) is an enzyme that belongs to the ADAM protein family of metalloproteases. ADAM17 plays a prominent role in the Notch signaling pathway. In this study, researchers demonstrated the discovery of ZLDI-8. ZLDI-8 is a novel inhibitor for Notch activating/cleaving enzyme ADAM-17. In particular, ZLDI-8...
JH-RE-06 is a Potent REV1-REV7 Interface Inhibitor for Chemotherapy Improvement
DNA-damaging chemotherapeutics, such as Cisplatin, have been the mainstay of cancer treatment for decades. These therapies generate DNA lesions, and high-fidelity replicative DNA polymerases as the template cannot utilization. Thus, it blocks the progression of the replication fork, generates cytotoxicity, and ultimately causes cell death. However, cells employ specialized...
CCT020312 is a Selective Activator of EIF2AK3/PERK
Genetic alterations that disable G1/S checkpoint control and loss of this checkpoint often happen in human cancer. The mechanisms contribute to cancer generation by permitting inappropriate proliferation and distorting fate-driven cell cycle exit. Therefore, the active compounds activate the G1/S checkpoint. And they may represent a broadly applicable and...
NG25, a Dual Inhibitor of TAK1 and MAP4K2, Enhances Doxorubicin-mediated Apoptosis in Breast Cancer
In previous blog, we described NG25 as a potent dual TAK1 and MAP4K2 inhibitor. The compound shows excellent inhibition for inhibiting IKKβ activation by TLR7 and TLR9 agonists. Today, I’d like to introduce the anti-tumor activity of NG25 in breast cancer. A study from Zhenyu Wang carried out a...
ACY-1083, a Highly Selective HDAC6 Inhibitor, Reverses Chemotherapy-induced Peripheral Neuropathy
Nerves carry messages from the brain to the rest of the body. Peripheral neuropathy occurs when the peripheral nervous system is damaged. Chemotherapy-induced peripheral neuropathy is one of the most commonly and widely reported adverse side effects of cancer treatment. The symptoms of cemotherapy-induced peripheral neuropathy include pain, numbness, tingling,...